These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9302758)

  • 1. Perspectives on FIV vaccine development.
    Elyar JS; Tellier MC; Soos JM; Yamamoto JK
    Vaccine; 1997; 15(12-13):1437-44. PubMed ID: 9302758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
    Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
    AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.
    Sahay B; Yamamoto JK
    Viruses; 2018 May; 10(5):. PubMed ID: 29789450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.
    Leutenegger CM; Boretti FS; Mislin CN; Flynn JN; Schroff M; Habel A; Junghans C; Koenig-Merediz SA; Sigrist B; Aubert A; Pedersen NC; Wittig B; Lutz H
    J Virol; 2000 Nov; 74(22):10447-57. PubMed ID: 11044089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine.
    Bęczkowski PM; Harris M; Techakriengkrai N; Beatty JA; Willett BJ; Hosie MJ
    Vaccine; 2015 Feb; 33(8):977-84. PubMed ID: 25613718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of protection against feline immunodeficiency virus infection among domestic cats in New Zealand vaccinated with the Fel-O-Vax® FIV vaccine.
    Stickney A; Ghosh S; Cave NJ; Dunowska M
    Vet Microbiol; 2020 Nov; 250():108865. PubMed ID: 33045631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.
    Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE
    J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of a vaccine against feline immunodeficiency virus.
    Hosie MJ
    Br Vet J; 1994; 150(1):25-39. PubMed ID: 8025833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental vaccine protection against feline immunodeficiency virus.
    Yamamoto JK; Okuda T; Ackley CD; Louie H; Pembroke E; Zochlinski H; Munn RJ; Gardner MB
    AIDS Res Hum Retroviruses; 1991 Nov; 7(11):911-22. PubMed ID: 1662057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
    Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats.
    Burkhard MJ; Valenski L; Leavell S; Dean GA; Tompkins WA
    Vaccine; 2002 Dec; 21(3-4):258-68. PubMed ID: 12450701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
    Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
    Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
    Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats.
    Matteucci D; Poli A; Mazzetti P; Sozzi S; Bonci F; Isola P; Zaccaro L; Giannecchini S; Calandrella M; Pistello M; Specter S; Bendinelli M
    J Virol; 2000 Dec; 74(23):10911-9. PubMed ID: 11069985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feline immunodeficiency virus model for designing HIV/AIDS vaccines.
    Yamamoto JK; Sanou MP; Abbott JR; Coleman JK
    Curr HIV Res; 2010 Jan; 8(1):14-25. PubMed ID: 20210778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.
    Coleman JK; Pu R; Martin M; Sato E; Yamamoto JK
    AIDS; 2005 Sep; 19(14):1457-66. PubMed ID: 16135898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses.
    Sahay B; Aranyos AM; Mishra M; McAvoy AC; Martin MM; Pu R; Shiomitsu S; Shiomitsu K; Dark MJ; Sanou MP; Roff SR; Rathore MH; Yamamoto JK
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30717485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine.
    Sahay B; Aranyos AM; McAvoy A; Yamamoto JK
    Methods Mol Biol; 2018; 1808():197-219. PubMed ID: 29956186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passive antibody protection of cats against feline immunodeficiency virus infection.
    Hohdatsu T; Pu R; Torres BA; Trujillo S; Gardner MB; Yamamoto JK
    J Virol; 1993 Apr; 67(4):2344-8. PubMed ID: 8383246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
    Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
    AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.